Importer of Controlled Substances; Notice of Application, Fisher Clinical Services, Inc., 67396-67397 [2012-27437]
Download as PDF
<![CDATA[
67396
Federal Register / Vol. 77, No. 218 / Friday, November 9, 2012 / Notices
INTERNATIONAL TRADE
COMMISSION
INTERNATIONAL TRADE
COMMISSION
[USITC SE–12–031]
[USITC Se–12–030]
Government In The Sunshine Act
Meeting Notice
Government in the Sunshine Act
Meeting Notice
United
States International Trade Commission.
AGENCY HOLDING THE MEETING:
AGENCY HOLDING THE MEETING:
TIME AND DATE:
United
States International Trade Commission.
TIME AND DATE:
November 15, 2012 at
DEPARTMENT OF JUSTICE
9:30 a.m.
Room 101, 500 E Street SW.,
Washington, DC 20436, Telephone:
(202) 205–2000.
November 14, 2012 at
11:00 a.m.
PLACE:
Room 101, 500 E Street SW.,
Washington, DC 20436, Telephone:
(202) 205–2000.
PLACE:
STATUS:
STATUS:
Open to the public.
MATTERS TO BE CONSIDERED:
1. Agendas for future meetings: none
2. Minutes
3. Ratification List
4. Vote in Inv. Nos. 701–TA–487 and
731–TA–1197 (Final) (Steel Wire
Garment Hangers from Taiwan).
The Commission is currently
scheduled to transmit its
determinations and Commissioners’
opinions to the Secretary of
Commerce on or before November
29, 2012.
5. Outstanding action jackets: none
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
may be carried over to the agenda of the
following meeting.
Open to the public.
MATTERS TO BE CONSIDERED:
1. Agendas for future meetings: none
2. Minutes
3. Ratification List
4. Vote in Inv. Nos. 701–TA–482–484
and 731–TA–1191–1194
(Final)(Circular Welded CarbonQuality Steel Pipe from India,
Oman, the United Arab Emirates,
and Vietnam). The Commission is
currently scheduled to transmit its
determinations and Commissioners’
opinions to the Secretary of
Commerce on or before November
28, 2012.
5. Outstanding action jackets: none
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
may be carried over to the agenda of the
following meeting.
By order of the Commission.
Issued: November 7, 2012.
William R. Bishop,
Supervisory Hearings and Information
Officer.
By order of the Commission.
Issued: November 7, 2012.
William R. Bishop,
Supervisory Hearings and Information
Officer.
[FR Doc. 2012–27484 Filed 11–7–12; 11:15 am]
[FR Doc. 2012–27483 Filed 11–7–12; 11:15 am]
BILLING CODE 7020–02–P
BILLING CODE 7020–02–P
Notice of Lodging of Proposed
Consent Decree Under The
Comprehensive Environmental
Response, Compensation, and Liability
Act
On November 5, 2012, the Department
of Justice lodged a proposed consent
decree with the United States District
Court for the Western District of
Washington in the lawsuit entitled
United States v. Index Sportsmen, Inc.
(aka Index Sportsmen Club), Civil
Action No. 12–1949.
The United States filed this CERCLA
lawsuit on behalf of the United States
Forest Service. The complaint requests
recovery of costs that the United States
incurred responding to releases of
hazardous substances at the Index
Shooting Range Site in the Mt. BakerSnoqualmie National Forest near Index,
Washington. Index Sportsmen, Inc.,
operated a trap shooting range at the site
for more than 60 years and the site is
contaminated with lead and arsenic
from discarded shot. The proposed
consent decree requires total payments
of about $687,000, which includes
$600,000 to be paid by American States
Insurance Company. In return, the
United States agrees not to sue the
defendant under sections 106 and 107(a)
of CERCLA.
The publication of this notice opens
a period for public comment on the
consent decree. Comments should be
addressed to the Assistant Attorney
General, Environment and Natural
Resources Division, and should refer to
United States v. Index Sportsmen, Inc.,
D.J. Ref. No. 90–11–3–10090. All
comments must be submitted no later
than thirty (30) days after the
publication date of this notice.
Comments may be submitted either by
email or by mail:
Send them to:
By e-mail ......................................................................................
By mail .........................................................................................
tkelley on DSK3SPTVN1PROD with NOTICES
To submit comments:
pubcomment-ees.enrd@usdoj.gov.
Assistant Attorney General U.S. DOJ—ENRD P.O. Box 7611 Washington,
D.C. 20044–7611.
During the public comment period,
the consent decree may be examined
and downloaded at this Justice
Department Web site: https://
www.usdoj.gov/enrd/
Consent_Decrees.html. We will provide
a paper copy of the Consent Decree
upon written request and payment of
reproduction costs. Please mail your
request and payment to: Consent Decree
Library, U.S. DOJ—ENRD, P.O. Box
7611, Washington, DC 20044–7611.
VerDate Mar<15>2010
17:34 Nov 08, 2012
Jkt 229001
Please enclose a check or money order
for $5.75 (25 cents per page
reproduction cost) payable to the United
States Treasury.
Robert E. Maher, Jr.,
Acting Deputy Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2012–27436 Filed 11–8–12; 8:45 am]
BILLING CODE 4410–15–P
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application, Fisher Clinical
Services, Inc.
Pursuant to Title 21 Code of Federal
Regulations 1301.34(a), this is notice
that on August 20, 2012, Fisher Clinical
Services, Inc., 7554 Schantz Road,
E:\FR\FM\09NON1.SGM
09NON1
Federal Register / Vol. 77, No. 218 / Friday, November 9, 2012 / Notices
67397
July 26, 2012, 77 FR 43861, Boehringer
Ingelheim Chemicals, Inc., 2820 N.
Normandy Drive, Petersburg, Virginia
23805, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
Phenylacetone (8501), a basic class of
controlled substance listed in schedule
II.
The company plans to import the
listed controlled substance to bulk
manufacture amphetamine.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Boehringer Ingelheim Chemicals, Inc.,
to import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971.
DEA has investigated Boehringer
Ingelheim, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic class of controlled
substance listed.
Schedule
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than January 8, 2013.
Dated: November 1, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Dated: November 1, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Allentown, Pennsylvania 18106, made
application to the Drug Enforcement
Administration (DEA) for registration as
an importer of Tapentadol (9780), a
basic class of controlled substance listed
in schedule II.
The company plans to import the
listed controlled substance to conduct
clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
listed in schedule II, which falls under
the authority of section 1002(a)(2)(B) of
the Act (21 U.S.C. 952(a)(2)(B)) may, in
the circumstances set forth in 21 U.S.C.
958(i), file comments or objections to
the issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR
§ 1301.43 and in such form as
prescribed by 21 CFR § 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 10, 2012.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, 40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substances in schedules
I or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR § 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: November 1, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–27437 Filed 11–8–12; 8:45 am]
BILLING CODE 4410–09–P
tkelley on DSK3SPTVN1PROD with NOTICES
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer Of Controlled Substances;
Notice of Registration; Boehringer
Ingelheim Chemicals, Inc.
By Notice dated July 17, 2012, and
published in the Federal Register on
VerDate Mar<15>2010
17:34 Nov 08, 2012
Jkt 229001
[FR Doc. 2012–27440 Filed 11–8–12; 8:45 am]
Drug
Gamma
Hydroxybutyric
Acid
(2010).
Codeine-N-oxide (9053) ...............
Dihydromorphine (9145) ...............
Morphine-N-oxide (9307) .............
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Codeine (9050) II Dihydrocodeine
(9120).
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
Carfentanil (9743) .........................
Tapentadol (9780) ........................
Fentanyl (9801) ............................
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
[FR Doc. 2012–27394 Filed 11–8–12; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Noramco, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 9, 2012,
Noramco, Inc., 1440 Olympic Drive,
Athens, Georgia 30601, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Johnson Matthey, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on September 10,
2012, Johnson Matthey, Inc.,
Pharmaceuticals Materials, 900 River
Road, Conshohocken, Pennsylvania
19428, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
E:\FR\FM\09NON1.SGM
09NON1
]]>Agencies
[Federal Register Volume 77, Number 218 (Friday, November 9, 2012)]
[Notices]
[Pages 67396-67397]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-27437]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application, Fisher
Clinical Services, Inc.
Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this
is notice that on August 20, 2012, Fisher Clinical Services, Inc., 7554
Schantz Road,
[[Page 67397]]
Allentown, Pennsylvania 18106, made application to the Drug Enforcement
Administration (DEA) for registration as an importer of Tapentadol
(9780), a basic class of controlled substance listed in schedule II.
The company plans to import the listed controlled substance to
conduct clinical trials.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance listed in schedule II, which falls under the authority of
section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may, in the
circumstances set forth in 21 U.S.C. 958(i), file comments or
objections to the issuance of the proposed registration and may, at the
same time, file a written request for a hearing on such application
pursuant to 21 CFR Sec. 1301.43 and in such form as prescribed by 21
CFR Sec. 1316.47.
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than December 10, 2012.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR Sec. 1301.34(b),
(c), (d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import a basic class of any controlled substances
in schedules I or II are, and will continue to be, required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR Sec. 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: November 1, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-27437 Filed 11-8-12; 8:45 am]
BILLING CODE 4410-09-P
